Stock Market News1 month Merck’s BLA for RSV Antibody Clesrovimab Gets FDA Acceptance Zacks
The FDA accepts MRK’s BLA for clesrovimab, its monoclonal antibody, to protect infants from RSV disease. A decision from the agency is due on June 10, 2025.
XThe FDA accepts MRK’s BLA for clesrovimab, its monoclonal antibody, to protect infants from RSV disease. A decision from the agency is due on June 10, 2025.
X